Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Fostamatinib · Tavalisse, R935788

Small molecule · Inhibitor of spleen tyrosine kinase (SYK) · developed by Rigel Pharms

Approved FDA, Apr 2018
RIGL Developer
4 Registered trials

What is Fostamatinib?

Fostamatinib is an oral tyrosine kinase inhibitor of spleen tyrosine kinase (SYK). Its active metabolite R406 inhibits signaling through Fc-activating receptors and the B-cell receptor, reducing antibody-mediated destruction of platelets. It is studied in immune thrombocytopenia, warm antibody autoimmune hemolytic anemia, IgA nephropathy, ovarian cancer, and viral pneumonia including COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Tavalisse, R935788, R788
Drug type
Small molecule
Targets
spleen tyrosine kinase (SYK)
Mechanism
Inhibitor of spleen tyrosine kinase (SYK)
Pathways
Fc-activating receptor signal transduction, B-cell receptor signaling, antibody-mediated platelet destruction
Therapy area
Immunology, Oncology, Respiratory
Developer
Rigel Pharms (RIGL)
FDA status
Approved as Tavalisse (April 17, 2018), NDA209299 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Nov 5, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04629703 Phase 3 Covid19 Completed RIGL
NCT02612558 Phase 2 Warm Antibody Autoimmune Hemolytic Anemia Completed RIGL
NCT02112838 Phase 2 IGA Nephropathy Completed RIGL
NCT03246074 Phase 1 Ovarian Cancer Completed RIGL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Covid19IGA NephropathyOvarian CancerPneumoniaPneumonia, ViralSARS (Severe Acute Respiratory Syndrome)SARS PneumoniaWarm Antibody Autoimmune Hemolytic Anemia

Other drugs acting on SYK

More from Rigel Pharms

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RIGL page.

Follow RIGL, the company behind Fostamatinib

See RIGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RIGL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.